A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Membranous Nephropathy
- Nephrotic Syndrome
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 79 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04278729
- Collaborators
- American College of Clinical Pharmacy
- Investigators
- Principal Investigator: Daniel Crona, PharmD, PhD University of North Carolina, Chapel Hill